A Phase 1B Multiple Dose Study to Evaluate the Safety, Tolerability and Microbiome Dynamics of SER-287 in Subjects With Mild-to-Moderate Ulcerative Colitis.
Phase of Trial: Phase I
Latest Information Update: 02 Oct 2017
At a glance
- Drugs SER 287 (Primary)
- Indications Ulcerative colitis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Seres Therapeutics
- 02 Oct 2017 Status changed from active, no longer recruiting to completed according to a Seres Therapeutics media release.
- 02 Oct 2017 The Company intends to present detailed study results at a future medical/scientific meeting, according to a Seres Therapeutics media release.
- 02 Oct 2017 Top-line results presented in a Seres Therapeutics media release.